Turnover
≈ €340,000 estimated
The micro format states no turnover.
MEDPHAR
Lifetime
19 annual accounts with figures on one time axis, 22 filings since 2003peak €162,385 (2016)
€113,640▼ 1.8%
lowest -€26,936 (2020)
€2,323▼ 91.8%
peak €66,830 (2016)
€65,546▲ 3.7%
€190,312▼ 2.0%
peak 1 FTE (2006)
-not published
Board1 name since 2004
1 director
Documentsfilings and deeds
31-07-2026on the last day
2025micro format
Result from €28,467 to €2,323Cash from €5,260 to €8,265
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 3,986 companies had the same profile as MEDPHAR has now. Each dot stands for 10 companies, two years later.
96.4%
were still trading
2.4%
stopped another way
1.1%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,986 companies, not a prediction for MEDPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0478156946
New director
appointed, resigned · Director discharge: · General meeting of 27-12-2023 · Gazette deed
First establishment
PHARMACIE MEDPHAR, Renkinstraat 29, Schaerbeek
Incorporation
published on 22-08-2002 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| MEDPHAR Schaerbeek | €255,858 | €113,640 | 25.6% | - |
| PHARMACIE COLONIALE Ixelles | €261,567 | €128,561 | 86.3% | 1.2 |
| PHARMACIE GUSTIN Faimes | €265,567 | €122,521 | 32.9% | 1.9 |
| POGGE Schaerbeek | €285,910 | €128,031 | 34.5% | 2 |
| Parry Schaerbeek | €228,483 | €127,519 | -1.4% | 1.1 |
| PHARMACIE JOSAPHAT Schaerbeek | €298,824 | €115,565 | 41.3% | - |
| Magistra - Pharma Schaerbeek | €304,456 | €118,127 | 61.7% | - |
These companies have the same main activity as MEDPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €228,000 and €304,000, founded between 1998 and 2006.
Official details
Source: KBO- Status
- Active since 08-08-2002Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment unit
- 2.115.080.4461030 Schaerbeek, since 04-11-2002
- Financial year end
- 31 December
- Peppol
- Reachable since 19-12-2025
Annual accounts 2025
- €255,858▼ 0.6%
- Filing
- Filed on 31-07-2026, on the last day of the filing period
Insights on MEDPHAR
MEDPHAR files the micro format. That format states no turnover. The gross margin rose from €65,737 in 2006 to €113,640 in 2025.
The balance sheet grew most from 2008 to 2010 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about MEDPHAR
- What is the company number of MEDPHAR?
- The company number of MEDPHAR is 0478.156.946. The VAT number is the same number with BE in front: BE 0478.156.946.
- Where is MEDPHAR based?
- The registered office is at Renkinstraat 29, 1030 Schaerbeek.Company details
- What does MEDPHAR do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of MEDPHAR?
- MEDPHAR is a private limited company (BV).
- When was MEDPHAR founded?
- MEDPHAR was founded on 08-08-2002.
- Is MEDPHAR still active?
- Yes, MEDPHAR is an active enterprise in the KBO register.
- How many employees does MEDPHAR have?
- MEDPHAR had an average of 1 full-time equivalents in financial year 2021, according to the filed annual accounts.Financials
- What is the turnover of MEDPHAR?
- The turnover in financial year 2025 is ≈ €340,000. This figure is estimated from the gross margin of €113,640 and 31 comparable companies (NACE 477). It probably lies between €240,000 and €650,000.
- Is MEDPHAR profitable?
- In financial year 2025, MEDPHAR made a profit of €2,323.
- Where can I find the annual accounts of MEDPHAR?
- MEDPHAR filed 22 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of MEDPHAR due?
- MEDPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.